← All trials
NCT03063541
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2017
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Feb 24, 2017
- Last posted
- Jan 25, 2019
- Enrollment
- 776
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MannheimLead sponsor
- Koordinierungszentren für Klinische Studien bzw. Zentren für klinische StudienCollaborator
- Utrecht UniversityCollaborator
- University of MannheimReponsible party - principal investigator
- University of HamburgCollaborator
- University of MannheimSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.